


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+5.49%
+4.12%
+1.76%
+2.01%
INCY
Incyte Corp.
$102.09
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market
INCY Price Performance
$102.52 (-0.42%)
$85.38 (+19.57%)
$81.61 (+25.09%)
$73.47 (+38.95%)
INCY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

INCY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Above analyst estimates

Revenue increase YoY

Eps growth
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
INCY Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
INCY Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
What is INCY current stock price?
What are INCY stock strengths?
What is INCY Risk Level?
What is INCY market cap and volume?
What is INCY current Stock IQ?
Should I buy INCY stock right now?
Is INCY a Strong Buy right now?
What does a 'Strong Buy' rating mean for INCY?
What does a 'Strong Sell' rating mean for INCY?
What factors influence INCY's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+5.49%
+4.12%
+1.76%
+2.01%
INCY
Incyte Corp.
Current Price
$102.09
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Outperform the market

INCY Price Performance
$102.52 (-0.42%)
$85.38 (+19.57%)
$81.61 (+25.09%)
$73.47 (+38.95%)
INCY Analysts Opinion
INCY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Above analyst estimates

Revenue increase YoY

Eps growth
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
INCY Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
INCY Street Sentiment is extremely bullish and have positive views on the near-term outlook
INCY has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
INCY Stock IQ
INCY Latest Analysis
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer. ) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse .The trial evaluated tafasitamab and lenalidomide in addition to R-CHOP (rituximab cyclophosphamide doxorubicin vincristine and prednisone) compared to R-CHOP alone.The trial met its primary endpoint of progression-free survival (PFS). The trial als
Today
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?. Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mon Dec 22, 2025
Incyte Japan gains approval for Minjuvi with rituximab and lenalidomide to treat relapsed follicular lymphoma.
Mon Dec 22, 2025
Incytes Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma . (RTTNews) - Incyte Corp. (INCY) announced on Thursday that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of
Thu Dec 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
INCY Stock trends
INCY Stock performance
INCY Stock analysis
INCY investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.